Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Przerywana stymulacja Theta-Burst w celu poprawy objawów negatywnych i funkcji poznawczych w schizofrenii (ITBS-NKS-2024)

15 września 2026 zaktualizowane przez: Schülke, Rasmus Dr., Hannover Medical School

Intermittierende Theta-Burst-Stimulation Zur Verbesserung Von Negativsymptomatik Und Kognition Bei Schizophrenie

The planned randomized, sham-controlled, double-blind, monocentric study aims to evaluate the effectiveness of intermittent Theta-Burst Stimulation (iTBS) on negative symptoms and cognitive deficits in schizophrenia. Both the cerebellar vermis and the left dorsolateral prefrontal cortex will be stimulated successively within the same session.

The goal of this trial is to learn if intermittent theta-burst stimulation (iTBS) of the cerebellum and the left dorsolateral prefrontal cortext (DLPFC) can treat negative symptoms and improve cognition in patients with schizophrenia. The main question it aims to answer is:

Does iTBS of the cerebellum and the left DLPFC improve negative symptoms in patients with schizophrenia? Researchers will compare iTBS to sham stimulation to see if iTBS improves negative symptoms.

Participants will:

  • Receive 10 sessions of iTBS over the course of 2 weeks
  • Undergo extensive examination before iTBS treatment, immediately after iTBS treatment and 4 weeks after iTBS treatment. The examination includes assessment of negative symptoms; psychometric assessment of cognition, social cognition, depressive symptoms; functional magnetic resonance imaging; assessment of eye movements; blood and saliva sampling; assessment of adverse events and stimulation associated sensations.

The study thus seeks to determine whether iTBS of the fronto-cerebellar network might improve negative symptoms and cognition by altering the network's functional activity. Additionally, it will investigate whether a pro-inflammatory cytokine profile could affect iTBS outcomes and whether inflammatory markers could be affected by iTBS.

Przegląd badań

Typ studiów

Interwencyjne

Zapisy (Szacowany)

60

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

    • Lower Saxony
      • Hanover, Lower Saxony, Niemcy, 30625
        • Rekrutacyjny
        • Hannover Medical School
        • Kontakt:
        • Główny śledczy:
          • Rasmus Schülke, MD (Dr. med.)

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 65 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Diagnosis of schizophrenia (ICD-10: F20.-)
  • Age: 18-65 years
  • Ability to give informed consent
  • Signed informed consent form

Exclusion Criteria:

  • Any electronic implants
  • Non-MRI-compatible metal implants (e.g., pacemaker, cochlear implant, insulin pump, metal fragment injuries, work in the metal-processing industry)
  • Non-TMS-compatible metal implants (compatible items include: earrings, piercings, dental fillings, crowns, implants)
  • Claustrophobia
  • Epilepsy
  • History of traumatic brain injury within the last 3 months
  • History of stroke
  • Active central nervous system (CNS) infection
  • History of CNS infection within the last 3 months
  • Pregnancy
  • Current drug, medication, or alcohol abuse
  • Simultaneous participation in another clinical trial
  • Planned changes in psychopharmacological medication within the next 2 weeks
  • Severe physical illnesses that could endanger the patient, affect the examinations or make the MRI scanning cause additional burden

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: iTBS

Active intermittent theta-burst stimulation of the cerebellar vermis and the left dorsolateral prefrontal cortex

Intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex

Pozorny komparator: Sham iTBS

Sham intermittent theta-burst stimulation of the cerebellar vermis and the left dorsolateral prefrontal cortex

Sham intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change in negative symptoms
Ramy czasowe: From enrollment to the end of iTBS treatment

Change in negative symptoms, measured with the Clinical Assessment Interview for Negative Symptoms (CAINS). Higher CAINS scores correspond to more negative symptoms. The minimum total score is 0 points, the maximum total score is 52 points.

From enrollment to the end of iTBS treatment

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change in negative symptoms at 4-week follow-up
Ramy czasowe: From enrollment to follow-up 4 weeks after the end of iTBS treatment

Change in negative symptoms, measured with the Clinical Assessment Interview for Negative Symptoms (CAINS). Higher CAINS scores correspond to more negative symptoms. The minimum total score is 0 points, the maximum total score is 52 points.

From enrollment to follow-up 4 weeks after the end of iTBS treatment
Speech-gesture rating task
Ramy czasowe: From enrollment to the end of iTBS treatment

Accuracy and speed of evaluations in the Speech-Gesture Rating Task.

From enrollment to the end of iTBS treatment
Speech-gesture rating task at 4-week follow-up
Ramy czasowe: From enrollment to follow-up 4 weeks after the end of iTBS treatment

Accuracy and speed of evaluations in the Speech-Gesture Rating Task at 4-week follow-up.

From enrollment to follow-up 4 weeks after the end of iTBS treatment
Eye-Tracking Task
Ramy czasowe: From enrollment to the end of iTBS treatment

Changes in eye movements in the Eye-Tracking Task.

From enrollment to the end of iTBS treatment
Eye-Tracking Task at 4-week follow-up
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS treatment

Changes in eye movements in the Eye-Tracking Task at 4-week follow-up.

From enrollment to 4 weeks after the end of iTBS treatment
Reading the Mind in the Eyes Test
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS treatment

Reading the Mind in the Eyes Test.

From enrollment to 4 weeks after the end of iTBS treatment
Reading the Mind in the Eyes Test at 4-week follow-up
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS treatment

Reading the Mind in the Eyes Test at 4-week follow-up.

From enrollment to 4 weeks after the end of iTBS treatment
N-Back Test
Ramy czasowe: From enrollment to the end of iTBS treatment

Working memory performance in the N-Back Test (sensitivity index).

From enrollment to the end of iTBS treatment
N-Back Test at 4-week follow-up
Ramy czasowe: From enrollment to the end of iTBS treatment

Working memory performance in the N-Back Test (sensitivity index) 4 weeks after the end of iTBS treatment.

From enrollment to the end of iTBS treatment
FMRI: Resting-state functional connectivity
Ramy czasowe: From enrollment to the end of iTBS treatment

Changes in resting-state functional connectivity in functional magnetic resonance imaging. Focus on connectivity between cerebellar vermis and DLPFC.

From enrollment to the end of iTBS treatment
FMRI: Resting-state functional connectivity at 4-week follow-up
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS treatment

Changes in resting-state functional connectivity in functional magnetic resonance imaging. Focus on connectivity between cerebellar vermis and DLPFC.

From enrollment to 4 weeks after the end of iTBS treatment
FMRI: Task-related functional connectivity
Ramy czasowe: From enrollment to the end of iTBS treatment

Changes in task-related functional connectivity in functional magnetic resonance imaging, for the N-Back-task and the speech-gesture rating task.

From enrollment to the end of iTBS treatment
FMRI: Task-related functional connectivity at 4-week follow-up
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS treatment

Changes in task-related functional connectivity in functional magnetic resonance imaging, for the N-Back-task and the speech-gesture rating task.

From enrollment to 4 weeks after the end of iTBS treatment
Inflammatory cytokines
Ramy czasowe: From enrollment to the end of iTBS treatment

Concentrations of inflammatory cytokines (especially IL-6 and TNF-α) in serum and saliva.

From enrollment to the end of iTBS treatment
Inflammatory cytokines at 4-week follow-up
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS treatment

Concentrations of inflammatory cytokines (especially IL-6 and TNF-α) in serum and saliva.

From enrollment to 4 weeks after the end of iTBS treatment
Stimulation-associated perceptions
Ramy czasowe: From the beginning of each iTBS stimulation to after the end of each iTBS stimulation

Stimulation-associated perceptions, measured using the TMS Adverse Events and Associated Sensations Questionnaire (TMSensQ, Section IV), after each iTBS session.

From the beginning of each iTBS stimulation to after the end of each iTBS stimulation
Therapy dropout rate
Ramy czasowe: From the beginning of iTBS treatment to the end of iTBS treatment

Therapy dropout rate (i.e. study termination).

From the beginning of iTBS treatment to the end of iTBS treatment
Serious Adverse Events (SAEs)
Ramy czasowe: From the beginning of iTBS treatment to the end of iTBS treatment

Serious Adverse Events (SAEs), measured using TMSensQ (Section V).

From the beginning of iTBS treatment to the end of iTBS treatment
Self-reported depression: BDI-II
Ramy czasowe: From enrollment to the end of iTBS-treatment

Self-reported depression, measured using the Beck Depression Inventory-II (BDI-II). Higher scores correspond to more depressive symptoms. The minimum total score is 0 points, the maximum total score is 63 points.

From enrollment to the end of iTBS-treatment
Self-reported depression at 4-week follow-up: BDI-II
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS-treatment

Self-reported depression, measured using the Beck Depression Inventory-II (BDI-II). Higher scores correspond to more depressive symptoms. The minimum total score is 0 points, the maximum total score is 63 points.

From enrollment to 4 weeks after the end of iTBS-treatment
Self-rated gesture perception and production: BAG
Ramy czasowe: From enrollment to the end of iTBS-treatment

Change in self-rated gesture perception and production, measured using the Brief Assessment of Gestures (BAG) questionnaire. Higher BAG scores correspond to greater engagement with or reliance on gestures in communication and indicate stronger tendencies to produce or perceive gestures effectively in different contexts. The minimum total score is 12 points, the maximum total score is 60 points.

From enrollment to the end of iTBS-treatment
Self-rated gesture perception and production at 4-week follow-up: BAG
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS-treatment

Change in self-rated gesture perception and production, measured using the Brief Assessment of Gestures (BAG) questionnaire. Higher BAG scores correspond to greater engagement with or reliance on gestures in communication and indicate stronger tendencies to produce or perceive gestures effectively in different contexts. The minimum total score is 12 points, the maximum total score is 60 points.

From enrollment to 4 weeks after the end of iTBS-treatment
Epigenetic changes of neurotrophic and immunological factors
Ramy czasowe: From enrollment to the end of iTBS treatment

Exploratory molecular biological investigations focusing on neurotrophic (e.g., BDNF, VEGF, GDNF) and immunological (e.g., TNF-alpha, IL-6, t-PA, S100A10) factors.

From enrollment to the end of iTBS treatment
Epigenetic changes of neurotrophic and immunological factors at 4-week follow-up
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS treatment

Exploratory molecular biological investigations focusing on neurotrophic (e.g., BDNF, VEGF, GDNF) and immunological (e.g., TNF-alpha, IL-6, t-PA, S100A10) factors.

From enrollment to 4 weeks after the end of iTBS treatment
Concentrations of markers of neuronal damage
Ramy czasowe: From enrollment to the end of iTBS treatment

Concentrations of markers of neuronal damage (e.g., NSE, S100-β) in serum.

From enrollment to the end of iTBS treatment
Concentrations of markers of neuronal damage at 4-week follow-up
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS treatment

Concentrations of markers of neuronal damage (e.g., NSE, S100-β) in serum.

From enrollment to 4 weeks after the end of iTBS treatment

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Rasmus Schülke, MD (Dr. med.), Hannover Medical School

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

8 kwietnia 2025

Zakończenie podstawowe (Szacowany)

31 grudnia 2026

Ukończenie studiów (Szacowany)

31 grudnia 2026

Daty rejestracji na studia

Pierwszy przesłany

14 grudnia 2024

Pierwszy przesłany, który spełnia kryteria kontroli jakości

14 grudnia 2024

Pierwszy wysłany (Rzeczywisty)

18 grudnia 2024

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

18 września 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

15 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIEZDECYDOWANY

Opis planu IPD

Whether IPD may be shared has not yet been decided. IPD might not be shared due to data protection laws.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

produkt wyprodukowany i wyeksportowany z USA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj